The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype

Steven Tucker; Alina Zorn

doi:10.1111/bph.15403

The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype

Steven Tucker^* (Corresponding Author), Alina Zorn

^*Corresponding author for this work

Medical Education

University of Aberdeen

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

3 Downloads (Pure)

Abstract

The Popeye domain‐containing protein 1 (POPDC1), a tight junction‐associated transmembrane protein with a unique binding site for cAMP, has been shown to act as a tumour suppressor in cancer cells. Through interaction with many downstream effectors and signalling pathways, POPDC1 promotes cell adhesion and inhibits uncontrolled cell proliferation, epithelial‐to‐mesenchymal transition and metastasis. However, POPDC1 expression is down‐regulated in many types of cancer, thereby reducing its tumour‐suppressive actions. This review discusses the role of POPDC1 in the progression of the malignant phenotype and highlights the broad range of benefits POPDC1 stabilisation may achieve therapeutically. Cancer stem cells (CSCs) are a key hallmark of malignancies and commonly promote treatment resistance. This article provides a comprehensive overview of CSC signalling mechanisms, many of which have been shown to be regulated by POPDC1 in other cell types, thus suggesting an additional therapeutic benefit for POPDC1‐stabilising anti‐cancer drugs.

Original language	English
Pages (from-to)	2829-2843
Number of pages	15
Journal	British Journal of Pharmacology
Volume	179
Issue number	12
Early online date	27 Feb 2021
DOIs	https://doi.org/10.1111/bph.15403
Publication status	Published - 1 Jun 2022

Bibliographical note

Research Funding
Carnegie Trust for the Universities of Scotland
ACKNOWLEDGEMENTS
We would like to thank the Carnegie Trust for the Universities of Scotland who supported this work with a vacation studentship.

Keywords

cAMP
cancer
cancer stem cells
epithelial‐to‐mesenchymal transition
metastasis
POPDC1
proliferation
to&#8208
mesenchymal transition
epithelial&#8208
epithelial-to-mesenchymal transition

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bph.15403Licence: CC BY-NC

Tucker_etal_BJP_The_role_of_VOR
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 2.36 MBLicence: CC BY-NC

Cite this

@article{27f9fe57117247d2a419d7a9d5fcef91,

title = "The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype",

abstract = "The Popeye domain‐containing protein 1 (POPDC1), a tight junction‐associated transmembrane protein with a unique binding site for cAMP, has been shown to act as a tumour suppressor in cancer cells. Through interaction with many downstream effectors and signalling pathways, POPDC1 promotes cell adhesion and inhibits uncontrolled cell proliferation, epithelial‐to‐mesenchymal transition and metastasis. However, POPDC1 expression is down‐regulated in many types of cancer, thereby reducing its tumour‐suppressive actions. This review discusses the role of POPDC1 in the progression of the malignant phenotype and highlights the broad range of benefits POPDC1 stabilisation may achieve therapeutically. Cancer stem cells (CSCs) are a key hallmark of malignancies and commonly promote treatment resistance. This article provides a comprehensive overview of CSC signalling mechanisms, many of which have been shown to be regulated by POPDC1 in other cell types, thus suggesting an additional therapeutic benefit for POPDC1‐stabilising anti‐cancer drugs.",

keywords = "cAMP, cancer, cancer stem cells, epithelial‐to‐mesenchymal transition, metastasis, POPDC1, proliferation, to&#8208, mesenchymal transition, epithelial&#8208, epithelial-to-mesenchymal transition",

author = "Steven Tucker and Alina Zorn",

note = "Research Funding Carnegie Trust for the Universities of Scotland ACKNOWLEDGEMENTS We would like to thank the Carnegie Trust for the Universities of Scotland who supported this work with a vacation studentship.",

year = "2022",

month = jun,

day = "1",

doi = "10.1111/bph.15403",

language = "English",

volume = "179",

pages = "2829--2843",

journal = "British Journal of Pharmacology",

issn = "0007-1188",

publisher = "Wiley-Blackwell ",

number = "12",

}

TY - JOUR

T1 - The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype

AU - Tucker, Steven

AU - Zorn, Alina

N1 - Research Funding Carnegie Trust for the Universities of Scotland ACKNOWLEDGEMENTS We would like to thank the Carnegie Trust for the Universities of Scotland who supported this work with a vacation studentship.

PY - 2022/6/1

Y1 - 2022/6/1

N2 - The Popeye domain‐containing protein 1 (POPDC1), a tight junction‐associated transmembrane protein with a unique binding site for cAMP, has been shown to act as a tumour suppressor in cancer cells. Through interaction with many downstream effectors and signalling pathways, POPDC1 promotes cell adhesion and inhibits uncontrolled cell proliferation, epithelial‐to‐mesenchymal transition and metastasis. However, POPDC1 expression is down‐regulated in many types of cancer, thereby reducing its tumour‐suppressive actions. This review discusses the role of POPDC1 in the progression of the malignant phenotype and highlights the broad range of benefits POPDC1 stabilisation may achieve therapeutically. Cancer stem cells (CSCs) are a key hallmark of malignancies and commonly promote treatment resistance. This article provides a comprehensive overview of CSC signalling mechanisms, many of which have been shown to be regulated by POPDC1 in other cell types, thus suggesting an additional therapeutic benefit for POPDC1‐stabilising anti‐cancer drugs.

AB - The Popeye domain‐containing protein 1 (POPDC1), a tight junction‐associated transmembrane protein with a unique binding site for cAMP, has been shown to act as a tumour suppressor in cancer cells. Through interaction with many downstream effectors and signalling pathways, POPDC1 promotes cell adhesion and inhibits uncontrolled cell proliferation, epithelial‐to‐mesenchymal transition and metastasis. However, POPDC1 expression is down‐regulated in many types of cancer, thereby reducing its tumour‐suppressive actions. This review discusses the role of POPDC1 in the progression of the malignant phenotype and highlights the broad range of benefits POPDC1 stabilisation may achieve therapeutically. Cancer stem cells (CSCs) are a key hallmark of malignancies and commonly promote treatment resistance. This article provides a comprehensive overview of CSC signalling mechanisms, many of which have been shown to be regulated by POPDC1 in other cell types, thus suggesting an additional therapeutic benefit for POPDC1‐stabilising anti‐cancer drugs.

KW - cAMP

KW - cancer

KW - cancer stem cells

KW - epithelial‐to‐mesenchymal transition

KW - metastasis

KW - POPDC1

KW - proliferation

KW - to&#8208

KW - mesenchymal transition

KW - epithelial&#8208

KW - epithelial-to-mesenchymal transition

UR - http://www.scopus.com/inward/record.url?scp=85101791053&partnerID=8YFLogxK

U2 - 10.1111/bph.15403

DO - 10.1111/bph.15403

M3 - Article

C2 - 33533478

SN - 0007-1188

VL - 179

SP - 2829

EP - 2843

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

IS - 12

ER -

The role of Popeye domain‐containing protein 1 (POPDC1) in the progression of the malignant phenotype

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this